Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results From a Multicenter National Registry
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (6) , e295-e303
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma
This publication has 28 references indexed in Scilit:
- Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based studyBritish Journal of Haematology, 2013
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment AssignmentJournal of Clinical Oncology, 2011
- Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesThe Lancet, 2010
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trialsBlood, 2010
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaBlood, 2007
- Age and acute myeloid leukemiaBlood, 2006
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002